FDA Revamps Draft Guidance on Protocols for CMC Changes Following Approval

Drug GMP Report
A A
The FDA has a slate of new recommendations companies should follow when submitting a comparability protocol assessing changes to the chemistry, manufacturing or controls of a drug or biologic after the agency has approved its production process.

To View This Article:

Login

Subscribe To Drug GMP Report

Buy This Article Now

Add this article to your cart for $40.00